Although the impact of USP7 inhibitors on both cell survival (NF-ĸB) and cell death (p53/MDM2) pathways is desirable in the context of cancer therapy, such broad activity is unlikely to be beneficial in an anti-inflammatory agent. Here, TP53 is linked to cancer.